FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole analog of AM-2201 and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM.
FUBIMINA acts as a reasonably potent agonist for the CB2 receptor (Ki = 23.45 nM), with 12x selectivity over CB1 (Ki = 296.1 nM), and does not fully substitute for Δ9-THC in rat discrimination studies.
Related benzimidazole derivatives have been reported to be highly selective agonists for the CB2 receptor.
See also AM-694 AM-1235 AM-2232 AM-2233 BIM-018 JWH-018 List of AM cannabinoids List of JWH cannabinoids THJ-2201
References